Mechanism of the anti-proliferative action of 25-hydroxy-19-nor-vitamin D 3 in human prostate cells

Journal of Molecular Endocrinology

Volumn 47, Issue 2, 2011, Pages 209-218

  Munetsuna, Eiji ^e   Nakabayashi, Sachie ^e   Kawanami, Rie ^e   Yasuda, Kaori ^e   Ohta, Miho ^b   Arai, Midori A ^c   Kittaka, Atsushi ^d   Chen, Tai C ^e   Kamakura, Masaki ^a   Ikushiro, Shinichi ^a   Sakaki, Toshiyuki ^a  

^a TOYAMA PREFECTURAL UNIVERSITY   (Japan)

^b Soai University   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d TEIKYO UNIVERSITY   (Japan)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXY 19 NOR VITAMIN D3; CALCIFEDIOL; OXYGENASE; STEROID 24 HYDROXYLASE; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ARTICLE; CONTROLLED STUDY; CYP24A1 GENE; DRUG ACTIVITY; DRUG RECEPTOR BINDING; GENE; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; HYDROXYLATION; MALE; PRIORITY JOURNAL; PROSTATE; PROTEIN TRANSPORT; TRANSACTIVATION;

BLOTTING, WESTERN; CALCITRIOL; CELL LINE; CELL PROLIFERATION; CHOLECALCIFEROL; HUMANS; PROTEIN TRANSPORT; RECEPTORS, CALCITRIOL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; STEROID HYDROXYLASES;

EID: 80054815905     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-11-0008     Document Type: Article

References (40)

1. Alvarez-Diaz S, Valle N, Garcia JM, Pena C, Freije JM, Quesada V, Astudillo A, Bonilla F, Lopez-Otin C & Munoz A 2009 Cystatin D is a candidate tumor suppressor gene induced by vitamin D in human colon cancer cells. Journal of Clinical Investigation 119 2343-2358. (doi:10.1172/JCI37205)
2. Arai A, Tsutsumi R, Hara H, Chen TC, Sakaki T, Urushino N, Inouye K & Kittaka A 2005 Synthesis of 25-hydroxy-19-norvitamin D3 analogs and their antiproliferative activities on prostate cells. Heterocycles 66 469-479. (doi:10.3987/COM-05-S(K)56)
3. Binderup L, Latini S, Binderup E, Bretting C, Calverley M & Hansen K 1991 20-epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses. Biochemical Pharmacology 42 1569-1575. (doi:10.1016/0006-2952(91)90426-6)
4. Bouillon R, Okamura WH & Norman AW 1995 Structure-function relationships in the vitamin D endocrine system. Endocrine Reviews 16 200-257. (doi:10.1210/edrv-16-2-200)
5. Chen TC & Holick MF 2003 Vitamin D and prostate cancer prevention and treatment. Trends in Endocrinology and Metabolism 14 423-430. (doi:10.1016/j.tem.2003.09.004)
6. Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL & Holick MF 2000 The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clinical Cancer Research 6 901-908.
7. Deluca HF, Prahl JM & Plum LA 2011 1,25-Dihydroxyvitamin D is not responsible for toxicity caused by vitamin D or 25-hydroxyvitamin D. Archives of Biochemistry and Biophysics 505 226-230. (doi:10.1016/j.abb.2010.10.012)
8. Dusso AS, Brown AJ & Slatopolsky E 2005 Vitamin D. American Journal of Physiology. Renal Physiology 289 F8-F28. (doi:10.1152/ajprenal.00336.2004)
9. Flanagan JN, Young MV, Persons KS, Wang L, Mathieu JS, Whitlatch LW, Holick MF & Chen TC 2006 Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D. Anticancer Research 26 2567-2572.
10. Glebocka A, Sokolowska K, Sicinski RR, Plum LA & Deluca HF 2009 New 1alpha,25-dihydroxy-19-norvitamin D(3) compounds constrained in a single A-ring conformation: synthesis of the analogues by ring-closing metathesis route and their biological evaluation. Journal of Medicinal Chemistry 52 3496-3504. (doi:10.1021/jm9001583)
11. Hsu JY, Feldman D, Mcneal JE & Peehl DM 2001 Reduced 1alphahydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Research 61 2852-2856.
12. Kittaka A, Suhara Y, Takayanagi H, Fujishima T, Kurihara M & Takayama H 2000 A concise and efficient route to 2alpha-(omegahydroxyalkoxy)-1alpha,25-dihydroxyvitamin D3: remarkably high affinity to vitamin D receptor. Organic Letters 2 2619-2622. (doi:10.1021/ol006222j)
13. Konno K, Fujishima T, Maki S, Liu Z, Miura D, Chokki M, Ishizuka S, Yamaguchi K, Kan Y, Kurihara M et al. 2000 Synthesis, biological evaluation, and conformational analysis of A-ring diastereomers of 2-methyl-1,25-dihydroxyvitamin D(3) and their 20-epimers: unique activity profiles depending on the stereochemistry of the A-ring and at C-20. Journal of Medicinal Chemistry 43 4247-4265. (doi:10.1021/jm000261j)
14. Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A & Slatopolsky E 1998 Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. American Journal of Kidney Diseases 32 S48-S54. (doi:10.1053/ajkd.1998.v32.pm9808143)
15. Lou YR, Laaksi I, Syvala H, Blauer M, Tammela TL, Ylikomi T & Tuohimaa P 2004 25-Hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells. FASEB Journal 18 332-334.
16. Lou YR, Molnar F, Perakyla M, Qiao S, Kalueff AV, St-Arnaud R, Carlberg C & Tuohimaa P 2010 25-Hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand. Journal of Steroid Biochemistry and Molecular Biology 118 162-170. (doi:10.1016/j.jsbmb.2009.11.011)
17. Martin KJ, Gonzalez EA, Gellens ME, Hamm LL, Abboud H & Lindberg J 1998 Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2. American Journal of Kidney Diseases 32 S61-S66.(doi:10.1053/ajkd.1998.v32.pm9808145)
18. Masuda S & Jones G 2006 Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Molecular Cancer Therapeutics 5 797-808. (doi:10.1158/1535-7163.MCT-05-0539)
19. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE & Upadhya P 1992 The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Research 52 515-520.
20. Munetsuna E, Hojo Y, Hattori M, Ishii H, Kawato S, Ishida A, Kominami SA & Yamazaki T 2009 Retinoic acid stimulates 17betaestradiol and testosterone synthesis in rat hippocampal slice cultures. Endocrinology 150 4260-4269. (doi:10.1210/en.2008-1644)
21. Ono K, Yoshida A, Saito N, Fujishima T, Honzawa S, Suhara Y, Kishimoto S, Sugiura T, Waku K, Takayama H et al. 2003 Efficient synthesis of 2-modified 1alpha,25-dihydroxy-19-norvitamin D3 with Julia olefination: high potency in induction of differentiation on HL-60 cells. Journal of Organic Chemistry 68 7407-7415. (doi:10.1021/jo034787y)
22. Posner GH, Helvig C, Cuerrier D, Collop D, Kharebov A, Ryder K, Epps T & Petkovich M 2010 Vitamin D analogues targeting CYP24 in chronic kidney disease. Journal of Steroid Biochemistry and Molecular Biology 121 13-19. (doi:10.1016/j.jsbmb.2010.03.065)
23. Prufer K & Barsony J 2002 Retinoid X receptor dominates the nuclear import and export of the unliganded vitamin D receptor. Molecular Endocrinology 16 1738-1751. (doi:10.1210/me.2001-0345)
24. Racz A & Barsony J 1999 Hormone-dependent translocation of vitamin D receptors is linked to transactivation. Journal of Biological Chemistry 274 19352-19360. (doi:10.1074/jbc.274.27.19352)
25. Rashid SF, Moore JS, Walker E, Driver PM, Engel J, Edwards CE, Brown G, Uskokovic MR & Campbell MJ 2001 Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene 20 1860-1872. (doi:10.1038/sj.onc.1204269)
26. Sakaki T, Sawada N, Takeyama K, Kato S & Inouye K 1999 Enzymatic properties of mouse 25-hydroxyvitamin D3 1 alpha-hydroxylase expressed in Escherichia coli. European ournal of Biochemistry 259 731-738. (doi:10.1046/j.1432-1327.1999.00096.x)
27. Sakaki T, Sawada N, Komai K, Shiozawa S, Yamada S, Yamamoto K, Ohyama Y & Inouye K 2000 Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24. European Journal of Biochemistry 267 6158-6165. (doi:10.1046/j.1432-1327.2000.01680.x)
28. Sakaki T, Kagawa N, Yamamoto K & Inouye K 2005 Metabolism of vitamin D3 by cytochromes P450. Frontiers in Bioscience 10 119-134. (doi:10.2741/1514)
29. Sawada N, Sakaki T, Ohta M & Inouye K 2000 Metabolism of vitamin D(3) by human CYP27A1. Biochemical and Biophysical Research Communications 273 977-984. (doi:10.1006/bbrc.2000.3050)
30. Sawada N, Kusudo T, Sakaki T, Hatakeyama S, Hanada M, Abe D, Kamao M, Okano T, Ohta M & Inouye K 2004 Novel metabolism of 1 alpha,25-dihydroxyvitamin D3 with C24-C25 bond cleavage catalyzed by human CYP24A1. Biochemistry 43 4530-4537. (doi:10.1021/bi030207f)
31. Schwartz GG, Hall MC, Stindt D, Patton S, Lovato J & Torti FM 2005 Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clinical Cancer Research 11 8680-8685. (doi:10.1158/1078-0432.CCR-05-1237)
32. Sicinski RR, Glebocka A, Plum LA & Deluca HF 2007 Design, synthesis, and biological evaluation of a 1alpha,25-dihydroxy-19-norvitamin D3 analogue with a frozen A-ring conformation. Journal of Medicinal Chemistry 50 6154-6164. (doi:10.1021/jm070635C)
33. Suhara Y, Nihei KI, Kurihara M, Kittaka A, Yamaguchi K, Fujishima T, Konno K, Miyata N & Takayama H 2001 Efficient and versatile synthesis of novel 2alpha-substituted 1alpha,25-dihydroxyvitamin D(3) analogues and their docking to vitamin D receptors. Journal of Organic Chemistry 66 8760-8771. (doi:10.1021/jo010375i)
34. Trump DL, Deeb KK & Johnson CS 2010 Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer Journal 16 1-9. (doi:10.1097/PPO.0b013e3181c51ee6)
35. Urushino N, Nakabayashi S, Arai MA, Kittaka A, Chen TC, Yamamoto K, Hayashi K, Kato S, Ohta M, Kamakura M et al. 2007 Kinetic studies of 25-hydroxy-19-nor-vitamin D3 and 1 alpha,25-dihydroxy-19-nor-vitamin D3 hydroxylation by CYP27B1 and CYP24A1. Drug Metabolism and Disposition 35 1482-1488. (doi:10.1124/dmd.107.015602)
36. Wang L, Flanagan JN, Whitlatch LW, Jamieson DP, Holick MF & Chen TC 2004 Regulation of 25-hydroxyvitamin D-1alpha-hydroxylase by epidermal growth factor in prostate cells. Journal of Steroid Biochemistry and Molecular Biology 89-90 127-130. (doi:10.1016/j.jsbmb.2004.03.091)
37. Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL, Rich ES, Holick MF & Chen TC 2002 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. Journal of Steroid Biochemistry and Molecular Biology 81 135-140. (doi:10.1016/S0960-0760(02)00053-5)
38. Yamada S, Shimizu M & Yamamoto K 2003 Structure-function relationships of vitamin D including ligand recognition by the vitamin D receptor. Medicinal Research Reviews 23 9-115. (doi:10.1002/med.10023)
39. Yang ES & Burnstein KL 2003 Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. Journal of Biological Chemistry 278 46862-46868. (doi:10.1074/jbc.M306340200)
40. Zierold C, Darwish HM & Deluca HF 1995 Two vitamin D response elements function in the rat 1,25-dihydroxyvitamin D 24-hydroxylase promoter. Journal of Biological Chemistry 270 1675-1678. (doi:10.1074/jbc.270.4.1675)